HomeProtein ExpressionGABA Transporters

GABA Transporters

Fast synaptic transmission requires a mechanism for rapid removal of transmitter molecules from the synaptic cleft, a task most often accomplished by transmitter clearance or degradation. High affinity transport proteins fulfill this role for a variety of neurotransmitters including GABA, the major inhibitory neurotransmitter in the CNS. GABA transporters utilize sodium and chloride electrochemical gradients to enable GABA sequestration in presynaptic nerve terminals and surrounding glia. Reversal of GABA transport, caused by high cytosolic sodium, may be physiologically relevant in retinal cells, cerebral neurons and Bergman glia where calcium-independent GABA release has been observed. Functional, structural and sequence conservation place these transporters within the larger family of sodium- and chloride-dependent transport proteins. 

As GABA transporter activities were initially discovered, categorization was accomplished according to sensitivities to pharmacological agents and apparent localization to specific cell types. This vital work led to the broad classifications of 'neuronal' and 'glial' GABA transporters as a useful first approximation. Subsequent cloning of a number of transporter cDNAs, and delineation of the pharmacological sensitivities and regional distributions of each, resolved a number of discrepancies arising from strict adherence to the previous nomenclature. Four transporters have been identified that transport GABA with varying affinities and are referred to as GAT-1, GAT-2, GAT-3 (or GAT-B) and BGT-1. Nipecotic acid serves as a universal inhibitor of and substrate for the GABA transporters with the exception of BGT-1. The most abundant transporter, GAT-1, found principally in neurons but also in specialized glia, transports GABA with high affinity and is inhibited by cis-1,3-aminocyclohexane carboxylic acid (ACHC) and L-diaminobutyric acid (L-DABA). Predominantly localized to pia mater and arachnoid complex, GAT-2 transports GABA with relatively high affinity and is inhibited by β-alanine. GAT-3, identified in both neuronal and glial cells, transports both GABA and β-alanine with relatively high affinity. Expressed in neurons throughout the brain, BGT-1 transports GABA at moderate affinity and the osmolyte betaine at low affinity. Additional pharmacological studies in heterologous high-level expression systems are now providing a new framework from which to probe the physiological roles of the individual GABA transport proteins.

Structural motifs common to these four GABA transporters include 12 transmembrane-spanning domains (TM), intracellular N- and C-termini, a large extracellular loop between TMs 3 and TM 4 having multiple potential glycosylation sites, and potential regulation on intracellular consensus phosphorylation sites. Pore-loop structures may also arise between TM 3 and TM 4 and also between TM 7 and TM 8.

A synaptic vesicle GABA transporter having ten TM domains and expressed in both GABAergic and glycinergic neurons has also been cloned. This transporter is inhibited most potently by vigabatrin (γ-vinyl-GABA), weakly by nipecotic acid and glycine, and utilizes both the Dy and DpH components of the proton electrochemical gradient (DmH+) to accomplish vesicular GABA uptake. In addition, glycine may be a potential substrate for this carrier.

The clinical relevance of GABA transporter modulation has arisen from extensive data suggesting that select anticonvulsants exert a majority of their effects at these transport sites. The number of transporters expressed in certain temporal lobe regions and the resulting potential for depolarization-induced transport reversal may also be of particular relevance in the clinical sphere of epilepsy. Because disruptions in GABAergic transmission have been implicated not only in epilepsy, but also in affective disorders and schizophrenia, each member of this family has become a potential target for pharmacological intervention. In addition, tiagabine has pronounced effects on promoting slow-wave sleep, making the GABA transporters potential targets for the treatment of sleep disruptions. With the exception of GAT-1, highly selective and potent inhibitors of each subtype have not been identified, although the potential for therapeutic benefit appears promising. Recent work with EF1502, an analog of exo-THPO with affinity for both mGAT-1 and mGAT-2, suggests that mGAT-2-selective inhibitors may have utility in treating epilepsy. Selective inhibitors or potentiators of individual GABA transporter subtypes may provide avenues for the fine tuning of GABA tonus in select CNS locales.

The Table below contains accepted modulators and additional information.


a) Relative affinity of BGT-1 for GABA is several fold higher than for betaine (93 µM and 398 µM, respectively).

b) These compounds are also substrates.

c) Potent and selective inhibitors of GAT-1 with IC50 values of 40-70 nm.

d) Selective inhibitor of GAT-3 with an IC50 value of 5 µM.

e) Selective inhibitor of GAT-3 and BGT-1 with Ki values of 1.6-6.1 µM.

f) Selective inhibitor of BGT-1 with a Ki value of 1.4 µM.

g) Vesicular GABA transporter is inhibited by vigabatrin with an IC50 similar to that for GABA (7.5 µM and 4.75 µM, respectively)

h) Selective inhibitor of mGAT-1 with an IC50 value of 4 µM.

i) Selective inhibitor of mGAT-1 and mGAT-2 with IC50 values of 4 and 22 µM, respectively.



ACHC: cis-1,3-Aminocyclohexane carboxylic acid
CI-966: [1-[2-bis[4-(Trifluoromethyl)phenyl]-methoxy]ethyl]-1,2,5,6-tetrahydro-3-pyridine carboxylic acid
L-DABA: L-Diaminobutyric acid
EF1502: [N-[4,4-bis(3-Methyl-2-thienyl)-3-butenyl]-3-hydroxy-4-(methylamino)-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol]
EGYT-3886: [(-)-2-Phenyl-2-[(dimethylamino)ethoxy]-(1R)-1,7,7-trimethylbi-cyclo[2.2.1]heptan]
LU-32-176B: [N-[4,4-bis(4-Fluorophenyl)-butyl]-3-hydroxy-4-amino-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol]
NNC 05-2045: 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(4-methoxyphenyl)-4-piperidinol
NNC 05-2090: 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol
NO-711: 1-(2-(((Diphenylmethylene)amino)oxyethyl)-1,2,4,6-tetrahydro-3-pyridine-carboxylic acid
SKF 89976A: N-(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acid
SNAP-5114: (S)-1-[2-[tris(4-Methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid
THPO: 4,5,6,7-Tetrahydro-isoxazolo[4,5-c]-pyridin-3-ol


Clark JE, Clark WA. 2001. Pharmacology of GABA Transporters.355-372.
Dalby NO. 2003. Inhibition of ?-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. European Journal of Pharmacology. 479(1-3):127-137.
Dhar TGM, Borden LA, Tyagarajan S, Smith KE, Branchek TA, Weinshank RL, Gluchowski C. 1994. Design, Synthesis and Evaluation of Substituted Triarylnipecotic Acid Derivatives as GABA Uptake Inhibitors: Identification of a Ligand with Moderate Affinity and Selectivity for the Cloned Human GABA Transporter GAT-3. J. Med. Chem.. 37(15):2334-2342.
Gonzalez-Burgos G. 2010. GABA Transporter GAT1: A Crucial Determinant of GABAB Receptor Activation in Cortical Circuits?.175-204.
Iversen L. Neurotransmitter transporters and their impact on the development of psychopharmacology. 147(S1):S82-S88.
Krogsgaard-Larsen P, Frolund B, Frydenvang K. 2000. GABA Uptake Inhibitors. Design, Molecular Pharmacology and Therapeutic Aspects. CPD. 6(12):1193-1209.
Leach JP, Brodie MJ. 1998. Tiagabine. The Lancet. 351(9097):203-207.
Madsen KK, White HS, Schousboe A. 2010. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacology & Therapeutics. 125(3):394-401.
McIntire SL, Reimer RJ, Schuske K, Edwards RH, Jorgensen EM. 1997. Identification and characterization of the vesicular GABA transporter. Nature. 389(6653):870-876.
O, Porter R, RJ. 1999. Jasper's Basic Mechanisms of the Epilepsies. Third Edition: Advances in Neurology, Vol. 7. Lippincott Williams & Wilkins: pp. 551-560.
Sagné C, El Mestikawy S, Isambert M, Hamon M, Henry J, Giros B, Gasnier B. 1997. Cloning of a functional vesicular GABA and glycine transporter by screening of genome databases. 417(2):177-183.
Sałat K, Kulig K. 2011. GABA transporters as targets for new drugs. Future Medicinal Chemistry. 3(2):211-222.
Sarup A, Larsson O, Schousboe A. 2003. GABA Transporters and GABA-Transaminase as Drug Targets. CDTCNSND. 2(4):269-277.
Schousboe A, Madsen KK, White HS. 2011. GABA transport inhibitors and seizure protection: the past and future. Future Medicinal Chemistry. 3(2):183-187.
Schousboe A, Sarup A, Bak L, Waagepetersen H, Larsson O. 2004. Role of astrocytic transport processes in glutamatergic and GABAergic neurotransmission. Neurochemistry International. 45(4):521-527.
Sofuoglu M, Kosten TR. 2006. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opinion on Emerging Drugs. 11(1):91-98.
Soudijn W, van Wijngaarden I. 2000. The GABA Transporter and its Inhibitors. CMC. 7(10):1063-1079.
White HS, Watson WP, Hansen SL, Slough S, Perregaard J, Sarup A, Bolvig T, Petersen G, Larsson OM, Clausen RP, et al. 2005. First Demonstration of a Functional Role for Central Nervous System Betaine/?-Aminobutyric Acid Transporter (mGAT2) Based on Synergistic Anticonvulsant Action among Inhibitors of mGAT1 and mGAT2. J Pharmacol Exp Ther. 312(2):866-874.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?